PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15636706-8	2005	Pretreatment with Fasudil abolished the enhancing effect of Ang II on vascular contraction produced by NE, and reduced the calcium sensitivity.	fasudil	18-25	angiotensinogen	Rattus norvegicus	60-66	
15834290-12	2005	Fasudil abrogated Ang II- and CGP42112A-mediated effects.	fasudil	0-7	angiotensinogen	Rattus norvegicus	18-24	
18689606-4	2008	In the present study, intravenous injections of fasudil reversed pulmonary hypertensive responses to intravenous infusion of the thromboxane receptor agonist, U-46619 and ventilation with a 10% O(2) gas mixture and inhibited pulmonary vasoconstrictor responses to intravenous injections of angiotensin II, BAY K 8644, and U-46619 without prior exposure to agonists, which can upregulate Rho-kinase activity.	fasudil	48-55	angiotensinogen	Rattus norvegicus	290-304	
11997258-5	2002	The distinct Rho-associated kinase (ROK) inhibitors HA-1077 and Y-27632, as well as the Rho inhibitor Clostridium botulinum C3 exoenzyme, also significantly attenuated ANG II- and LPA-stimulated Pyk2 tyrosine phosphorylation.	fasudil	52-59	angiotensinogen	Rattus norvegicus	168-174	
33258351-13	2020	The administration of fasudil and high-dose MXXTM significantly reduced the contents of HIF-1alpha, VEGF, PRA, ANG-II and ALD.	fasudil	22-29	angiotensinogen	Rattus norvegicus	111-117	
27346833-7	2016	Pre-incubation with fasudil (1, 3, or 10mumol/l) attenuated KCl (10-60mmol/l) and angiotensin II (Ang II; 1mumol/l)-induced vasoconstriction in mesenteric artery rings.	fasudil	20-27	angiotensinogen	Rattus norvegicus	82-96	
27346833-7	2016	Pre-incubation with fasudil (1, 3, or 10mumol/l) attenuated KCl (10-60mmol/l) and angiotensin II (Ang II; 1mumol/l)-induced vasoconstriction in mesenteric artery rings.	fasudil	20-27	angiotensinogen	Rattus norvegicus	98-104	
27346833-10	2016	In addition, fasudil could block the increased phosphorylation level of myosin light chain (MLC) and myosin-binding subunit of myosin phosphatase (MYPT1) induced by Ang II.	fasudil	13-20	angiotensinogen	Rattus norvegicus	165-171	
14500337-6	2003	Angiotensin II caused a perivascular accumulation of macrophages and Rho-kinase activation, both of which were also significantly suppressed by fasudil.	fasudil	144-151	angiotensinogen	Rattus norvegicus	0-14	
14500337-7	2003	Vascular NAD(P)H oxidase expression (nox1, nox4, gp91phox, and p22phox) and endothelial production of superoxide anions were markedly increased by angiotensin II, both of which were also significantly suppressed by fasudil.	fasudil	215-222	angiotensinogen	Rattus norvegicus	147-161	
22322975-5	2012	Inhibition of type 1 ANG II receptors (losartan, 1 muM) or Rho kinase (fasudil, 10 muM) prevented ANG II-induced RhoA-GEF downregulation.	fasudil	71-78	angiotensinogen	Rattus norvegicus	98-104	
19545435-9	2009	HA-1077 (10 microM), an inhibitor of ROCK1 activity, reduced AT-II efficacy (Deltamg/mg tissue w.w.) by -3.5 +/- 1.0, -4.6 +/- 1.9, -22.1 +/- 2.2 and -11.4 +/- 1.3 in N, NL, D and DL respectively).	fasudil	0-7	angiotensinogen	Rattus norvegicus	61-66	
18467645-8	2008	Aldo/Ang II synergistically activated RhoA/Rho kinase and VSMC migration, effects blocked by PP2, apocynin, and fasudil, inhibitors of c-Src, NADPH oxidase, and Rho kinase, respectively.	fasudil	112-119	angiotensinogen	Rattus norvegicus	5-11	
17049502-8	2006	Fasudil treatment reduced both MAP and RVR responses to Ang II in each group.	fasudil	0-7	angiotensinogen	Rattus norvegicus	56-62